WOMEN, THE GIRL CHILD AND HIV AND AIDS
PP1 Reaffirming
the Beijing Declaration and Platform for Action and the outcomes of its
reviews; the Convention on the Elimination of all Forms of Discrimination Against Women, the
outcome documents of the Twenty-third Special Session of the General Assembly, the
Programme of Action of the International Conference on Population and Development, and the
key actions for its further implementation and outcomes of its reviews, the Convention on the
Rights of the Child, the Declaration on the Elimination of Violence Against Women; the 2011
Political Declaration on HIV and AIDS; the UN Security Council Resolution 1325 on Women,
Peace and Security, the 2030 Agenda for Sustainable Development, including the Sustainable
Development Goals, in particular the resolve of Member States to end the AIDS epidemic by
2030.
PP2 Noting
with deep concern that the global HIV epidemic disproportionately affects women
and girls and acknowledging the progress achieved in the realisation of Goal 6 of the
Millennium Development Goals (MGDs), halting and reversing the spread of HIV where the
global response to HIV has averted millions of new HIV infections and AIDS-related deaths since
2000, when the MDGs were set;
PP3 Recognizing
the need to intensify efforts to end the AIDS epidemic through fast tracking
the HIV response across the prevention and treatment continuum, including in the context of
the UNAIDS 90-90-90 targets and acknowledging the specific vulnerabilities of adolescent and
young girls and women due to, inter alia, unequal power relations in society between women
and men, boys and girls;
PP4 Acknowledging
that prevention, treatment, care and support for people living with and
affected by HIV and AIDS are mutually reinforcing elements of an effective response that must
be integrated into a comprehensive multisectoral gender responsive approach to end the AIDS
epidemic;
PP5 Noting with concern
that regulations, policies and practices, including those that limit
legitimate trade of generic medicines, may seriously limit access to affordable HIV treatment
and other pharmaceutical products in low-and middle-income countries, and recognizing that
improvements can be made, inter alia through national legislation, regulatory policy and supply
chain management, and noting that reductions in barriers to affordable products could be
explored in order to expand access to affordable and good quality HIV prevention products,
diagnostics, medicine and treatment commodities for HIV, including opportunistic infections
and co-infections;
PP6 Stressing
that gender equality and the political, civil, social, economic and cultural
empowerment of women and girls as well as the full and equal enjoyment of their human rights
1